Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: An interim cohort analysis

International Journal of Tuberculosis and Lung Disease

Volumn 19, Issue 8, 2015, Pages 979-985

  Ndjeka, N ^a   Conradie, F ^b,c   Schnippel, K ^b,c   Hughes, J ^d   Bantubani, N ^e   Ferreira, H ^f   Maartens, G ^g   Mametja, D ^a   Meintjes, G ^g   Padanilam, X ^h   Variava, E ^b,e   Pym, A ⁱ   Pillay, Y ^a  

^a NATIONAL DEPARTMENT OF HEALTH   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c RIGHT TO CARE   (South Africa)

^d MÉDECINS SANS FRONTIÈRES   (Switzerland)

^e TB HIV Investigative Network of Kwazulu Natal   (South Africa)

^f Klerksdorp/Tshepong Hospital Complex   (South Africa)

^g UNIVERSITY OF CAPE TOWN   (South Africa)

^h Sizwe Tropical Diseases Hospital   (South Africa)

ⁱ AFRICA HEALTH RESEARCH INSTITUTE   (South Africa)

Author keywords

Adverse events; Compassionate access; Extensively drug resistant tuberculosis; South Africa

Indexed keywords

BEDAQUILINE; EFAVIRENZ; EMTRICITABINE; LOPINAVIR PLUS RITONAVIR; TENOFOVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; QUINOLINE DERIVATIVE; QUINOLONE DERIVATIVE; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; ATRIAL FIBRILLATION; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; DELUSION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; KIDNEY DISEASE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; PRIORITY JOURNAL; PSYCHOSIS; QTC INTERVAL; SOUTH AFRICAN; TREATMENT DURATION; TREATMENT OUTCOME; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FOLLOW UP; HIV INFECTIONS; MICROBIOLOGY; MIDDLE AGED; PREVALENCE; PROSPECTIVE STUDY; SOUTH AFRICA;

ADULT; ANTI-HIV AGENTS; ANTITUBERCULAR AGENTS; COHORT STUDIES; DIARYLQUINOLINES; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; FLUOROQUINOLONES; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PREVALENCE; PROSPECTIVE STUDIES; SOUTH AFRICA; TREATMENT OUTCOME;

EID: 84938255826     PISSN: 10273719     EISSN: 18157920     Source Type: Journal    
DOI: 10.5588/ijtld.14.0944     Document Type: Article

References (19)

1. World Health Organization. Global tuberculosis report, 2014. WHO/HTM/TB/2014.08. Geneva, Switzerland: WHO, 2014.
2. Gandhi N R, Shah N S, Andrews J R, et al. HIV coinfection in multidrug-and extensively drug-resistant tuberculosis results in high early mortality. AmJ Respir Crit Care Med 2010; 181: 80-86.
3. Diacon A H, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009; 360: 2397-2405.
4. Cox E, Laessig K. FDA approval of bedaquiline: the benefit-risk balance for drug-resistant tuberculosis. N Engl J Med 2014; 371: 689-691.
5. Diacon A H, Pym A, Grobusch M P, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med 2014; 371: 723-732.
6. Janssen Therapeutics. Sirturo: prescribing information. Beerse, Belgium: Janssen Pharmaceuticals, 2012: p 25.
7. Conradie F, Meintjes G, Hughes J, et al. Clinical access to Bedaquiline Programme for the treatment of drug-resistant tuberculosis. S Afr Med J 2014; 104: 164-166.
8. South African National Department of Health. The South African Antiretroviral Treatment Guidelines. Pretoria, South Africa: DoH, 2013.
9. Svensson E M, Aweeka F T, Park J G, Marzan F, Dooley K E, KarlssonMO.Model-based estimates of the effects of efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients coinfected with HIV and tuberculosis. Antimicrob Agents Chemother 2013; 57: 2780-2787.
10. Directorate Drug-Resistant TB, TB & HIV, South African Department of Health. Management of drug-resistant tuberculosis: policy guidelines. Pretoria, South Africa: Department of Health, 2011.
11. Noel G. Effects of three fluoroquinolones on QT interval in healthy adults after single doses. Clin Pharmacol Ther 2003; 73: 292-303.
12. World Health Organization. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis: interim policy guidance. WHO/HTM/TB/2013.6. Geneva, Switzerland: WHO, 2013. http://apps.who.int/iris/bitstream/10665/84879/1/9789241505482-eng.pdf Accessed April 2015.
13. University of Bern. STROBE (STrengthening the Reporting of OBservational studies in Epidemiology) guidelines. Bern, Switzerland: University of Bern, 2009. http://www.strobestatement. org Accessed May 2015.
14. Udwadia Z F, Amale R A,Mullerpattan J B. Initial experience of bedaquiline use in a series of drug-resistant tuberculosis patients from India. Int J Tuberc Lung Dis 2014; 18: 1315-1318.
15. Guglielmetti L, Le Du D, Jachym M, et al. Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: Interim analysis of a French cohort. Clin Infect Dis 2015; 60: 188-194.
16. Cox H, Hughes J, Moyo S, et al. Reduced time to treatment decentralised care and the rapid Xpert MTB/RIF test in Khayelitsha. 20th International AIDS Conference, 20-25 July 2014, Melbourne, VIC, Australia: International AIDS Society, 2014. [Oral Abstract MOAB0203] http://pag.aids2014.org/Abstracts.aspx?SID1142&AID8215 Accessed April 2015.
17. Dlamini-Mvelase N R,Werner L, Phili R, Cele L P,Mlisana K P. Effects of introducing Xpert MTB/RIF test on multi-drug resistant tuberculosis diagnosis in KwaZulu-Natal South Africa. BMC Infect Dis 2014; 14: 442.
18. Cox H, Ford N. Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and metaanalysis [Review]. Int J Tuberc Lung Dis 2012; 16: 447-454.
19. Sotgiu G, Centis R, D'Ambrosio L, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDRTB and XDR-TB: systematic review and meta-analysis. Eur Respir J 2012; 40: 1430-1442.